Cuprina gets Saudi classification for MEDIFLY
Cuprina Holdings reports a key regulatory milestone and a governance upgrade.
Rhea-AI Filing Summary
Cuprina Holdings reports a key regulatory milestone and a governance upgrade. Its 49%-owned associate, Cuprina MENA Co. Ltd, has received official product classification from the Saudi Food and Drug Authority for MEDIFLY, a medical-grade maggot debridement therapy. The SFDA has categorized MEDIFLY as a Medical Device–Drug combination product, primarily regulated under the medical device framework. This classification enables Cuprina to finalize scientific and technical requirements needed for commercial distribution across Saudi Arabia’s healthcare network, supporting its Middle East and North Africa expansion strategy.
The company also strengthened its Medical and Scientific Advisory Board by appointing Dr. Enming Yong, a consultant in endocrinology at Tan Tock Seng Hospital and Adjunct Senior Lecturer at the Lee Kong Chian School of Medicine in Singapore. Under a strategic advisory agreement, Dr. Yong will guide scientific and development strategy, clinical oversight, strategic consultation, and trend analysis in endocrinology and chronic wound management, reinforcing Cuprina’s focus on patient safety and clinical excellence.
Positive
- None.
Negative
- None.
Insights
Cuprina secures Saudi product classification for MEDIFLY and deepens clinical oversight.
Cuprina highlights an important step toward commercializing its MEDIFLY maggot debridement therapy in Saudi Arabia. Official SFDA classification as a Medical Device–Drug combination product defines the regulatory pathway and allows work on detailed scientific and technical requirements for market entry.
This action supports the company’s stated expansion strategy in the Middle East and North Africa, though the addressable market and timelines are not quantified here. Parallel appointment of endocrinologist Dr. Enming Yong to the Medical and Scientific Advisory Board should enhance clinical governance across chronic wound and metabolic-related programs.
Overall, the developments are strategically aligned but lack financial metrics in this excerpt. Future disclosures on Saudi commercialization progress, such as launch timing, reimbursement status, and early adoption, would help investors assess the revenue contribution from MEDIFLY and the impact of strengthened advisory oversight.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What regulatory milestone did Cuprina Holdings (CUPR) achieve in Saudi Arabia?
What is MEDIFLY in Cuprina Holdings’ product portfolio?
How does the Saudi SFDA classification support Cuprina Holdings’ MENA strategy?
Who is Dr. Enming Yong and what role will he play at Cuprina Holdings (CUPR)?
How will Dr. Yong contribute to Cuprina Holdings’ clinical and scientific governance?
What sectors does Cuprina Holdings (CUPR) focus on beyond chronic wound care?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2026
Commission File Number: 001-42288
Cuprina Holdings (Cayman) Limited
(Registrant’s Name)
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
| Form 20-F ☒ | Form 40-F ☐ |
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On March 11, 2026, Cuprina Holdings (Cayman) Limited (the “Company”) issued a press release titled “Cuprina Holdings Announces Key Regulatory Milestone in Saudi Arabia and Strengthens Global Scientific Advisory Board”. This press release is furnished herewith as Exhibit 99.1.
Exhibits
| Exhibit No | Description | |
| 99.1 | Press Release dated March 11, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Cuprina Holdings (Cayman) Limited | ||
| By: | /s/ David Quek Yong Qi | |
| Name: | David Quek Yong Qi | |
| Title: | Chief Executive Officer and Director | |
Date: March 11, 2026
Exhibit 99.1
Cuprina Holdings Announces Key Regulatory Milestone in Saudi Arabia
and Strengthens Global Scientific Advisory Board
SINGAPORE, March 11, 2026 – Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced several strategic business developments, including a significant regulatory classification in Saudi Arabia and the expansion of its Medical and Scientific Advisory Board.
Regulatory Milestone in Saudi Arabia
Cuprina’s 49%-owned associate, Cuprina MENA Co. Ltd, has received official product classification from the Saudi Food and Drug Authority (SFDA) for MEDIFLY, the Company’s medical-grade maggot debridement therapy. The SFDA has classified MEDIFLY as a Medical Device–Drug combination product, with the primary mode of action regulated under the medical device framework.
This classification, which allows the Company to finalize the scientific and technical requirements necessary for the commercial distribution of MEDIFLY across Saudi Arabia’s healthcare network, is a critical milestone in Cuprina’s expansion strategy for the Middle East and North Africa (MENA) region.
Expansion of Medical and Scientific Advisory Board
The Company is also pleased to announce the appointment of Enming Yong to its Medical and Scientific Advisory Board. Dr. Yong is a highly respected Consultant in the Department of Endocrinology at Tan Tock Seng Hospital (TTSH) and serves as an Adjunct Senior Lecturer at the Lee Kong Chian School of Medicine, both located in Singapore. A graduate of the National University of Singapore (NUS) and a member of the Royal College of Physicians (UK), Dr. Yong brings deep clinical expertise in managing complex metabolic and endocrine conditions, particularly those intersecting with chronic wound care.
Under the terms of the strategic advisory agreement signed with Cuprina, Dr. Yong will provide high-level scientific governance, with duties including:
| ● | Scientific & Development Strategy. Reviewing and advising on scientific protocols, research proposals, and long-term product development strategies. | |
| ● | Clinical Oversight. Offering medical perspectives on clinical trials, patient safety protocols, and efficacy evaluations for Cuprina’s biotherapeutic pipeline. | |
| ● | Strategic Consultation. Participating in key consultations to address project milestones and navigate clinical challenges. | |
| ● | Trend Analysis. Providing expert advice on emerging trends in endocrinology and chronic wound management to ensure Cuprina remains at the forefront of medical innovation. |
Strengthening Regional Clinical Engagement
Cuprina continues to build strong momentum with the medical community in its core Asian markets through high-profile clinical engagements:
| ● | Hong Kong. Cuprina recently served as a key sponsor and exhibitor at the 2026 Symposium on Diabetic Wound Healing at The University of Hong Kong (HKU). The event, hosted by The Hong Kong Society for Diabetic Limb Care, allowed the Company to showcase MEDIFLY’s limb-salvage capabilities to leading specialists. |
●
| Singapore. The Company participated in Woodlands Health (WH) Research Day 2026, presenting its comprehensive product portfolio to clinicians and researchers within Singapore’s public healthcare cluster. In addition, Cuprina convened its inaugural Medical & Scientific Advisory Board Meeting on March 02, 2026. |
“The first quarter of 2026 has been defined by focused execution and the strengthening of our scientific foundation,” said Cuprina Chief Executive Officer Mr. David Quek Yong Qi, “Securing our regulatory classification for MEDIFLY in Saudi Arabia provides a clear commercial roadmap for the MENA region, but equally vital is the elevation of our clinical governance. The appointment of Dr. Yong is a transformative step for Cuprina; his profound expertise in endocrinology and leadership within Singapore’s public healthcare ecosystem will be instrumental as we refine our scientific protocols and scale our evidence-based solutions globally.
“Dr. Yong’s oversight ensures that our innovation remains deeply rooted in patient safety and clinical excellence as we address the global challenge of chronic wound care.”
About Cuprina Holdings (Cayman) Limited
We are a Singapore-based biomedical and biotechnology company dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the infertility, medical waste recycling, and health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit https:// www.cuprina.com.
FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg
Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email: info@skylineccg.com